Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer.

Published in: Expert opinion on biological therapy (2019)

Frontline pembrolizumab monotherapy remains the treatment of choice for patients with high PD-L1 expression. For those with low PD-L1 expression, pembrolizumab in combination with chemotherapy can be considered.

Keyphrases

advanced non small cell lung cancer
combination therapy
epidermal growth factor receptor
randomized controlled trial
locally advanced
drug delivery
open label
tyrosine kinase
decision making
smoking cessation